Symbols / GOSS Stock $0.36 -2.64% Gossamer Bio, Inc.
GOSS (Stock) Chart
Stock Fundamentals
|
|
|
|
|
|
About
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-23 | down | Cantor Fitzgerald | Overweight → Neutral | — |
| 2026-03-06 | main | HC Wainwright & Co. | Buy → Buy | $5 |
| 2026-03-05 | main | Oppenheimer | Outperform → Outperform | $3 |
| 2026-02-24 | down | Wedbush | Outperform → Neutral | $1 |
| 2026-02-24 | down | Barclays | Overweight → Underweight | $0 |
| 2026-02-24 | down | Leerink Partners | Outperform → Market Perform | $1 |
| 2026-01-28 | init | Barclays | — → Overweight | $9 |
| 2026-01-22 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2025-09-11 | reit | Cantor Fitzgerald | Overweight → Overweight | — |
| 2025-09-10 | up | UBS | Neutral → Buy | $9 |
| 2025-08-06 | main | Wedbush | Outperform → Outperform | $5 |
| 2025-07-14 | init | Scotiabank | — → Sector Outperform | $11 |
| 2025-05-16 | main | Goldman Sachs | Buy → Buy | $8 |
| 2025-05-16 | reit | Wedbush | Outperform → Outperform | $4 |
| 2025-04-17 | main | Goldman Sachs | Buy → Buy | $7 |
| 2025-03-14 | reit | Wedbush | Outperform → Outperform | $4 |
| 2025-01-30 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-11-11 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-09-17 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-08-30 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
- Analysts Remain Bullish on Gossamer Bio (GOSS) Despite Phase 3 Setback - Yahoo Finance Sun, 12 Apr 2026 07
- GOSS Investor Alert: Gossamer Bio Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Misrepresented Patient Enrollment Quality: SueWallSt - Morningstar hu, 30 Apr 2026 13
- Bragar Eagel & Squire, P.C. Reminds Gossamer Investors that - GlobeNewswire Fri, 01 May 2026 16
- Gossamer Bio (NASDAQ:GOSS) Stock Price Down 5.8% - Time to Sell? - MarketBeat ue, 21 Apr 2026 07
- Robbins LLP Urges GOSS Stockholders to Contact the Firm for Information About the Class Action Against Gossamer Bio, Inc. - ChartMill Wed, 29 Apr 2026 23
- Nasdaq warns Gossamer Bio (NASDAQ: GOSS) over sub-$1 share price - Stock Titan hu, 09 Apr 2026 07
- Gossamer Bio, Inc. (GOSS) Stock Analysis: Potential 717% Upside In The Biotech Arena - DirectorsTalk Interviews hu, 16 Apr 2026 07
- GOSS Investor Alert: Gossamer Bio Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Overstated Trial Prospects: Levi & Korsinsky - PR Newswire Wed, 22 Apr 2026 13
- GOSS Investor Alert: Gossamer Bio Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Concealing Placebo Response Risks: Levi & Korsinsky - Morningstar Wed, 29 Apr 2026 13
- GOSS Investor Alert: Gossamer Bio Securities Fraud Lawsuit - GlobeNewswire Mon, 27 Apr 2026 22
- INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Gossamer Bio, Inc. of Class Action Lawsuit and Upcoming Deadlines - GOSS - ChartMill hu, 30 Apr 2026 23
- Here's Why Gossamer Bio (GOSS) Is a Great 'Buy the Bottom' Stock Now - Yahoo Finance hu, 26 Feb 2026 08
- [ARS] Gossamer Bio, Inc. SEC Filing - Stock Titan Fri, 24 Apr 2026 20
- Lost Money on Gossamer Bio, Inc. (GOSS)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm - Morningstar ue, 28 Apr 2026 13
- INVESTOR NOTICE: Gossamer Bio, Inc. (GOSS) Investors with - GlobeNewswire ue, 28 Apr 2026 23
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
48.47
-57.74%
|
114.70
|
0.00
|
0.00
|
| Operating Revenue |
|
48.47
-57.74%
|
114.70
|
0.00
|
0.00
|
| Operating Expense |
|
211.72
+21.25%
|
174.62
+0.50%
|
173.76
-20.49%
|
218.53
|
| Research And Development |
|
174.09
+25.71%
|
138.49
+2.35%
|
135.30
-20.84%
|
170.92
|
| Selling General And Administration |
|
37.63
+4.15%
|
36.13
-6.04%
|
38.45
-19.23%
|
47.61
|
| General And Administrative Expense |
|
37.63
+4.15%
|
36.13
-6.04%
|
38.45
-19.23%
|
47.61
|
| Other Gand A |
|
37.63
+4.15%
|
36.13
-6.04%
|
38.45
-19.23%
|
47.61
|
| Total Expenses |
|
211.72
+21.25%
|
174.62
+0.50%
|
173.76
-20.49%
|
218.53
|
| Operating Income |
|
-163.25
-172.46%
|
-59.92
+65.52%
|
-173.76
+20.49%
|
-218.53
|
| Total Operating Income As Reported |
|
-170.73
-184.93%
|
-59.92
+67.39%
|
-183.76
+15.94%
|
-218.59
|
| EBITDA |
|
-158.47
-296.49%
|
-39.97
+75.32%
|
-161.92
+23.29%
|
-211.07
|
| Normalized EBITDA |
|
-150.99
-277.79%
|
-39.97
+73.69%
|
-151.92
+28.00%
|
-211.00
|
| Reconciled Depreciation |
|
1.00
-75.86%
|
4.15
-5.34%
|
4.38
-0.99%
|
4.43
|
| EBIT |
|
-159.47
-261.46%
|
-44.12
+73.47%
|
-166.31
+22.83%
|
-215.50
|
| Total Unusual Items |
|
-7.47
|
0.00
+100.00%
|
-10.00
-15284.62%
|
-0.07
|
| Total Unusual Items Excluding Goodwill |
|
-7.47
|
0.00
+100.00%
|
-10.00
-15284.62%
|
-0.07
|
| Special Income Charges |
|
-7.47
|
0.00
+100.00%
|
-10.00
-15284.62%
|
-0.07
|
| Other Special Charges |
|
7.47
|
—
|
10.00
+15284.62%
|
0.07
|
| Net Income |
|
-170.37
-201.39%
|
-56.53
+68.56%
|
-179.82
+21.61%
|
-229.38
|
| Pretax Income |
|
-170.46
-206.39%
|
-55.63
+69.06%
|
-179.82
+21.61%
|
-229.38
|
| Net Non Operating Interest Income Expense |
|
-9.02
+7.38%
|
-9.74
+15.42%
|
-11.51
+6.37%
|
-12.30
|
| Interest Expense Non Operating |
|
10.99
-4.58%
|
11.52
-14.76%
|
13.51
-2.66%
|
13.88
|
| Net Interest Income |
|
-9.02
+7.38%
|
-9.74
+15.42%
|
-11.51
+6.37%
|
-12.30
|
| Interest Expense |
|
10.99
-4.58%
|
11.52
-14.76%
|
13.51
-2.66%
|
13.88
|
| Interest Income Non Operating |
|
1.97
+10.74%
|
1.78
-10.92%
|
2.00
+26.15%
|
1.58
|
| Interest Income |
|
1.97
+10.74%
|
1.78
-10.92%
|
2.00
+26.15%
|
1.58
|
| Other Income Expense |
|
1.81
-87.06%
|
14.02
+157.00%
|
5.46
+277.06%
|
1.45
|
| Other Non Operating Income Expenses |
|
9.29
-33.75%
|
14.02
-9.28%
|
15.46
+922.22%
|
1.51
|
| Tax Provision |
|
-0.09
-109.85%
|
0.89
|
0.00
|
0.00
|
| Tax Rate For Calcs |
|
0.00
-100.00%
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-170.37
-201.39%
|
-56.53
+68.56%
|
-179.82
+21.61%
|
-229.38
|
| Net Income From Continuing Operation Net Minority Interest |
|
-170.37
-201.39%
|
-56.53
+68.56%
|
-179.82
+21.61%
|
-229.38
|
| Net Income From Continuing And Discontinued Operation |
|
-170.37
-201.39%
|
-56.53
+68.56%
|
-179.82
+21.61%
|
-229.38
|
| Net Income Continuous Operations |
|
-170.37
-201.39%
|
-56.53
+68.56%
|
-179.82
+21.61%
|
-229.38
|
| Normalized Income |
|
-162.90
-188.17%
|
-56.53
+66.71%
|
-169.82
+25.95%
|
-229.31
|
| Net Income Common Stockholders |
|
-170.37
-201.39%
|
-56.53
+68.56%
|
-179.82
+21.61%
|
-229.38
|
| Diluted EPS |
|
-0.75
-200.00%
|
-0.25
+78.81%
|
-1.18
+56.46%
|
-2.71
|
| Basic EPS |
|
-0.75
-200.00%
|
-0.25
+78.81%
|
-1.18
+56.46%
|
-2.71
|
| Basic Average Shares |
|
228.52
+1.01%
|
226.23
+48.23%
|
152.62
+80.46%
|
84.57
|
| Diluted Average Shares |
|
228.52
+1.01%
|
226.23
+48.23%
|
152.62
+80.46%
|
84.57
|
| Diluted NI Availto Com Stockholders |
|
-170.37
-201.39%
|
-56.53
+68.56%
|
-179.82
+21.61%
|
-229.38
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
172.25
-45.37%
|
315.29
+1.08%
|
311.92
+14.49%
|
272.45
|
| Current Assets |
|
167.64
-45.90%
|
309.89
+1.10%
|
306.52
+17.05%
|
261.88
|
| Cash Cash Equivalents And Short Term Investments |
|
136.93
-53.51%
|
294.52
-0.64%
|
296.43
+15.94%
|
255.68
|
| Cash And Cash Equivalents |
|
37.73
-18.11%
|
46.07
+43.49%
|
32.11
-71.32%
|
111.97
|
| Other Short Term Investments |
|
99.20
-60.07%
|
248.44
-6.00%
|
264.32
+83.93%
|
143.71
|
| Receivables |
|
12.23
+129.06%
|
5.34
|
0.00
|
—
|
| Other Receivables |
|
12.23
+129.06%
|
5.34
|
—
|
—
|
| Prepaid Assets |
|
—
|
—
|
—
|
6.20
|
| Restricted Cash |
|
—
|
—
|
—
|
0.00
|
| Other Current Assets |
|
18.48
+84.26%
|
10.03
-0.61%
|
10.09
+62.75%
|
6.20
|
| Total Non Current Assets |
|
4.61
-14.79%
|
5.40
+0.13%
|
5.40
-48.94%
|
10.57
|
| Net PPE |
|
4.20
-18.04%
|
5.12
+7.16%
|
4.78
-51.68%
|
9.89
|
| Gross PPE |
|
4.40
-16.97%
|
5.30
-48.06%
|
10.21
-36.19%
|
16.00
|
| Accumulated Depreciation |
|
-0.21
-13.11%
|
-0.18
+96.63%
|
-5.43
+11.13%
|
-6.11
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Machinery Furniture Equipment |
|
—
|
0.00
-100.00%
|
1.27
-5.78%
|
1.35
|
| Construction In Progress |
|
—
|
—
|
0.00
-100.00%
|
0.08
|
| Other Properties |
|
4.33
-18.44%
|
5.30
-16.83%
|
6.38
-46.89%
|
12.01
|
| Leases |
|
0.08
|
0.00
-100.00%
|
2.56
+0.00%
|
2.56
|
| Other Non Current Assets |
|
0.41
+44.17%
|
0.28
-54.21%
|
0.62
-9.12%
|
0.68
|
| Total Liabilities Net Minority Interest |
|
295.01
+3.22%
|
285.80
+14.71%
|
249.15
-4.31%
|
260.37
|
| Current Liabilities |
|
63.44
+40.94%
|
45.01
-12.77%
|
51.60
+4.81%
|
49.23
|
| Payables And Accrued Expenses |
|
31.30
+108.60%
|
15.00
-43.14%
|
26.39
+25.07%
|
21.10
|
| Payables |
|
5.96
+157.22%
|
2.32
-58.03%
|
5.53
+278.75%
|
1.46
|
| Accounts Payable |
|
5.96
+156.96%
|
2.32
-58.03%
|
5.53
+278.75%
|
1.46
|
| Current Accrued Expenses |
|
25.33
+99.72%
|
12.69
-39.20%
|
20.86
+6.22%
|
19.64
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
11.21
-6.54%
|
11.99
+16.52%
|
10.29
-23.94%
|
13.53
|
| Total Tax Payable |
|
0.01
|
0.00
|
—
|
—
|
| Income Tax Payable |
|
0.01
|
0.00
|
—
|
—
|
| Current Debt And Capital Lease Obligation |
|
0.94
-2.39%
|
0.96
-93.56%
|
14.91
+2.19%
|
14.60
|
| Current Debt |
|
—
|
—
|
11.61
+0.00%
|
11.61
|
| Other Current Borrowings |
|
—
|
—
|
11.61
+0.00%
|
11.61
|
| Current Capital Lease Obligation |
|
0.94
-2.39%
|
0.96
-70.90%
|
3.30
+10.69%
|
2.98
|
| Current Deferred Liabilities |
|
19.99
+17.23%
|
17.05
|
0.00
|
—
|
| Current Deferred Revenue |
|
19.99
+17.23%
|
17.05
|
0.00
|
—
|
| Total Non Current Liabilities Net Minority Interest |
|
231.57
-3.83%
|
240.79
+21.89%
|
197.55
-6.44%
|
211.14
|
| Long Term Debt And Capital Lease Obligation |
|
201.97
+0.02%
|
201.92
+2.21%
|
197.55
-6.44%
|
211.14
|
| Long Term Debt |
|
198.51
+0.50%
|
197.52
+0.06%
|
197.41
-4.96%
|
207.70
|
| Long Term Capital Lease Obligation |
|
3.46
-21.33%
|
4.40
+2954.17%
|
0.14
-95.82%
|
3.45
|
| Non Current Deferred Liabilities |
|
29.61
-23.83%
|
38.87
|
0.00
|
—
|
| Non Current Deferred Revenue |
|
29.61
-23.83%
|
38.87
|
0.00
|
—
|
| Stockholders Equity |
|
-122.76
-516.25%
|
29.49
-53.02%
|
62.77
+419.74%
|
12.08
|
| Common Stock Equity |
|
-122.76
-516.25%
|
29.49
-53.02%
|
62.77
+419.74%
|
12.08
|
| Capital Stock |
|
0.02
+4.35%
|
0.02
+0.00%
|
0.02
+130.00%
|
0.01
|
| Common Stock |
|
0.02
+4.35%
|
0.02
+0.00%
|
0.02
+130.00%
|
0.01
|
| Share Issued |
|
233.68
+3.12%
|
226.60
+0.53%
|
225.41
+138.72%
|
94.42
|
| Ordinary Shares Number |
|
233.68
+3.12%
|
226.60
+0.53%
|
225.41
+138.72%
|
94.42
|
| Additional Paid In Capital |
|
1,321.30
+1.89%
|
1,296.85
+1.70%
|
1,275.14
+22.04%
|
1,044.86
|
| Retained Earnings |
|
-1,438.94
-13.43%
|
-1,268.57
-4.66%
|
-1,212.04
-17.42%
|
-1,032.22
|
| Gains Losses Not Affecting Retained Earnings |
|
-5.15
-533.05%
|
1.19
+439.71%
|
-0.35
+39.02%
|
-0.57
|
| Other Equity Adjustments |
|
-5.15
-533.05%
|
1.19
+439.71%
|
-0.35
+39.02%
|
-0.57
|
| Total Equity Gross Minority Interest |
|
-122.76
-516.25%
|
29.49
-53.02%
|
62.77
+419.74%
|
12.08
|
| Total Capitalization |
|
75.75
-66.63%
|
227.01
-12.74%
|
260.17
+18.38%
|
219.77
|
| Working Capital |
|
104.21
-60.66%
|
264.88
+3.91%
|
254.92
+19.88%
|
212.65
|
| Invested Capital |
|
75.75
-66.63%
|
227.01
-16.47%
|
271.79
+17.46%
|
231.39
|
| Total Debt |
|
202.91
+0.01%
|
202.88
-4.51%
|
212.46
-5.88%
|
225.74
|
| Net Debt |
|
160.78
+6.16%
|
151.45
-14.39%
|
176.91
+64.82%
|
107.34
|
| Capital Lease Obligations |
|
4.40
-17.93%
|
5.36
+55.51%
|
3.45
-46.40%
|
6.43
|
| Net Tangible Assets |
|
-122.76
-516.25%
|
29.49
-53.02%
|
62.77
+419.74%
|
12.08
|
| Tangible Book Value |
|
-122.76
-516.25%
|
29.49
-53.02%
|
62.77
+419.74%
|
12.08
|
| Interest Payable |
|
0.83
+0.00%
|
0.83
-13.95%
|
0.97
-9.11%
|
1.06
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-171.27
-4838.47%
|
-3.47
+97.82%
|
-159.16
+14.90%
|
-187.03
|
| Cash Flow From Continuing Operating Activities |
|
-171.27
-4838.47%
|
-3.47
+97.82%
|
-159.16
+14.90%
|
-187.03
|
| Net Income From Continuing Operations |
|
-170.37
-201.39%
|
-56.53
+68.56%
|
-179.82
+21.61%
|
-229.38
|
| Depreciation Amortization Depletion |
|
1.00
-75.86%
|
4.15
-5.34%
|
4.38
-0.99%
|
4.43
|
| Depreciation |
|
1.00
-75.86%
|
4.15
-5.34%
|
4.38
-0.99%
|
4.43
|
| Depreciation And Amortization |
|
1.00
-75.86%
|
4.15
-5.34%
|
4.38
-0.99%
|
4.43
|
| Other Non Cash Items |
|
8.46
+679.01%
|
1.09
-90.41%
|
11.32
+821.91%
|
1.23
|
| Stock Based Compensation |
|
10.55
-48.81%
|
20.62
-27.70%
|
28.52
-32.98%
|
42.55
|
| Operating Gains Losses |
|
-0.01
-100.62%
|
0.81
+11.02%
|
0.73
|
—
|
| Gain Loss On Investment Securities |
|
-0.01
|
—
|
—
|
—
|
| Gain Loss On Sale Of PPE |
|
0.00
-100.00%
|
0.81
+11.02%
|
0.73
|
0.00
|
| Change In Working Capital |
|
-13.63
-134.54%
|
39.46
+365.89%
|
-14.84
-232.83%
|
-4.46
|
| Change In Receivables |
|
-6.89
-29.06%
|
-5.34
|
0.00
|
0.00
|
| Change In Prepaid Assets |
|
-8.45
-13733.87%
|
0.06
+101.59%
|
-3.89
-1414.86%
|
0.30
|
| Change In Payables And Accrued Expense |
|
9.12
+212.20%
|
-8.13
-1.28%
|
-8.03
-229.87%
|
-2.43
|
| Change In Accrued Expense |
|
11.87
+283.31%
|
-6.48
+46.12%
|
-12.02
-1835.43%
|
-0.62
|
| Change In Payable |
|
-2.75
-65.88%
|
-1.66
-141.50%
|
3.99
+320.08%
|
-1.81
|
| Change In Account Payable |
|
-2.75
-65.88%
|
-1.66
-141.50%
|
3.99
+320.08%
|
-1.81
|
| Change In Other Working Capital |
|
-6.33
-111.31%
|
55.92
|
—
|
1.62
|
| Change In Other Current Assets |
|
-0.12
-137.31%
|
0.34
+440.32%
|
0.06
-84.50%
|
0.40
|
| Change In Other Current Liabilities |
|
-0.96
+71.62%
|
-3.39
-13.55%
|
-2.98
-9.59%
|
-2.72
|
| Investing Cash Flow |
|
156.36
+438.74%
|
29.02
+126.15%
|
-110.97
-10621.74%
|
-1.03
|
| Cash Flow From Continuing Investing Activities |
|
156.36
+438.74%
|
29.02
+126.15%
|
-110.97
-10621.74%
|
-1.03
|
| Net PPE Purchase And Sale |
|
-0.08
|
0.00
|
0.00
+100.00%
|
-0.41
|
| Purchase Of PPE |
|
-0.08
|
0.00
|
0.00
+100.00%
|
-0.41
|
| Capital Expenditure |
|
-0.08
|
—
|
—
|
-0.47
|
| Net Investment Purchase And Sale |
|
156.44
+439.01%
|
29.02
+126.15%
|
-110.97
-19716.07%
|
-0.56
|
| Purchase Of Investment |
|
-227.11
+54.10%
|
-494.78
-12.02%
|
-441.67
-85.53%
|
-238.06
|
| Sale Of Investment |
|
383.54
-26.78%
|
523.80
+58.39%
|
330.70
+39.24%
|
237.50
|
| Net Intangibles Purchase And Sale |
|
—
|
0.00
|
0.00
+100.00%
|
-0.07
|
| Purchase Of Intangibles |
|
—
|
0.00
|
0.00
+100.00%
|
-0.07
|
| Financing Cash Flow |
|
6.42
+155.93%
|
-11.49
-106.04%
|
190.15
+62.40%
|
117.09
|
| Cash Flow From Continuing Financing Activities |
|
6.42
+155.93%
|
-11.49
-106.04%
|
190.15
+62.40%
|
117.09
|
| Net Issuance Payments Of Debt |
|
0.00
+100.00%
|
-12.58
-8.34%
|
-11.61
-100.02%
|
-5.81
|
| Issuance Of Debt |
|
—
|
—
|
—
|
0.00
|
| Repayment Of Debt |
|
0.00
+100.00%
|
-12.58
-8.34%
|
-11.61
-100.02%
|
-5.81
|
| Long Term Debt Issuance |
|
—
|
—
|
—
|
0.00
|
| Long Term Debt Payments |
|
0.00
+100.00%
|
-12.58
-8.34%
|
-11.61
-100.02%
|
-5.81
|
| Net Long Term Debt Issuance |
|
0.00
+100.00%
|
-12.58
-8.34%
|
-11.61
-100.02%
|
-5.81
|
| Net Common Stock Issuance |
|
0.00
|
0.00
-100.00%
|
201.32
+67.84%
|
119.95
|
| Proceeds From Stock Option Exercised |
|
6.42
+487.83%
|
1.09
+146.17%
|
0.44
-84.95%
|
2.95
|
| Changes In Cash |
|
-8.48
-160.30%
|
14.07
+117.59%
|
-79.97
-12.68%
|
-70.98
|
| Effect Of Exchange Rate Changes |
|
0.14
+238.24%
|
-0.10
-192.73%
|
0.11
+121.28%
|
-0.52
|
| Beginning Cash Position |
|
46.07
+43.49%
|
32.11
-71.32%
|
111.97
-38.97%
|
183.47
|
| End Cash Position |
|
37.73
-18.11%
|
46.07
+43.49%
|
32.11
-71.32%
|
111.97
|
| Free Cash Flow |
|
-171.34
-4840.74%
|
-3.47
+97.82%
|
-159.16
+15.12%
|
-187.51
|
| Interest Paid Supplemental Data |
|
10.00
-5.31%
|
10.56
-14.05%
|
12.29
-3.34%
|
12.71
|
| Amortization Of Securities |
|
-7.28
+44.28%
|
-13.06
-38.22%
|
-9.45
-572.60%
|
-1.41
|
| Change In Interest Payable |
|
0.00
+100.00%
|
-0.14
-39.18%
|
-0.10
-9600.00%
|
-0.00
|
| Common Stock Issuance |
|
0.00
|
0.00
-100.00%
|
201.32
+67.84%
|
119.95
|
| Issuance Of Capital Stock |
|
0.00
|
0.00
-100.00%
|
201.32
+67.84%
|
119.95
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-04-09 View
- 42026-03-20 View
- 42026-03-20 View
- 42026-03-20 View
- 42026-03-20 View
- 42026-03-20 View
- 42026-03-20 View
- 8-K2026-03-17 View
- 10-K2026-03-17 View
- 8-K2026-02-23 View
- 42026-01-05 View
- 42026-01-05 View
- 42026-01-05 View
- 42026-01-05 View
- 42026-01-05 View
- 42026-01-05 View
- 8-K2025-11-05 View
- 10-Q2025-11-05 View
- 42025-10-02 View
- 42025-10-02 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|